12 results on '"Gotthardt D"'
Search Results
2. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in patients with cirrhosis
- Author
-
Stremmel Wolfgang, Giannitsis Evangelos, Weiss Karl, Weiss Celine, Lehrke Stephanie, Zahn Alexandra, Steen Henning, Lossnitzer Dirk, Sauer Peter, Katus Hugo A, and Gotthardt Daniel N
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Portal hypertension and cardiac alterations previously described as "cirrhotic cardiomyopathy" are known complications of end stage liver disease (ELD). Cardiac failure contributes to morbidity and mortality, particularly after liver transplantation and transjugular intrahepatic portosystemic shunt (TIPS). We sought to identify myocardial tissue characterization and evaluate cardiovascular magnetic resonance (CMR) for diagnosis of cardiac impairment. Results Twenty ELD patients underwent CMR for morphological, functional and tissue characterization by late gadolinium enhancement (LGE). Based on extent of LGE, patients were dichotomized into high and low LGE groups and analyzed regarding liver, cardiocirculatory and renal functions. CMR demonstrated hyperdynamic left ventricular function and a patchy pattern of LGE of the myocardium to a variable extent (range 2-62%) in all patients. There were no significant differences in Model for End-Stage Liver Disease (MELD), Child-Pugh score or the left ventricular ejection fraction between high and low LGE groups. QTc-interval was prolonged in 25% of the patients. E/A ratio was at the upper limit of norm; no difference between groups. Patients showing high LGE had a higher CI (p < 0.05). Biomarkers of myocardial stress were elevated. While NT-proBNP and c-Troponin-T showed no differences, PLGF and sFLT1 were lower in the high LGE group. Conclusion CMR shows myocardial involvement in patients with ELD resembling appearance of myocarditis. The hyperdynamic circulation in portal hypertension may be an important factor. Larger prospective trials are warranted to confirm the association with severity and outcome of liver disease and to test the predictive power of CMR for patients listed for liver transplantation.
- Published
- 2010
- Full Text
- View/download PDF
3. A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia.
- Author
-
Klein K, Kollmann S, Hiesinger A, List J, Kendler J, Klampfl T, Rhandawa M, Trifinopoulos J, Maurer B, Grausenburger R, Betram CA, Moriggl R, Rülicke T, Mullighan CG, Witalisz-Siepracka A, Walter W, Hoermann G, Sexl V, and Gotthardt D
- Subjects
- Animals, Mice, Humans, Disease Models, Animal, Cell Lineage genetics, Mutation, Mice, Transgenic, STAT5 Transcription Factor genetics, STAT5 Transcription Factor metabolism, Killer Cells, Natural metabolism, Killer Cells, Natural immunology, Killer Cells, Natural pathology, Leukemia, Large Granular Lymphocytic genetics, Leukemia, Large Granular Lymphocytic pathology
- Abstract
Abstract: Patients with T- and natural killer (NK)-cell neoplasms frequently have somatic STAT5B gain-of-function mutations. The most frequent STAT5B mutation is STAT5BN642H, which is known to drive murine T-cell leukemia, although its role in NK-cell malignancies is unclear. Introduction of the STAT5BN642H mutation into human NK-cell lines enhances their potential to induce leukemia in mice. We have generated a mouse model that enables tissue-specific expression of STAT5BN642H and have selectively expressed the mutated STAT5B in hematopoietic cells (N642Hvav/+) or exclusively in NK cells (N642HNK/NK). All N642Hvav/+ mice rapidly develop an aggressive T/NKT-cell leukemia, whereas N642HNK/NK mice display an indolent NK-large granular lymphocytic leukemia (NK-LGLL) that progresses to an aggressive leukemia with age. Samples from patients with NK-cell leukemia have a distinctive transcriptional signature driven by mutant STAT5B, which overlaps with that of murine leukemic N642HNK/NK NK cells. To our knowledge, we have generated the first reliable STAT5BN642H-driven preclinical mouse model that displays an indolent NK-LGLL progressing to aggressive NK-cell leukemia. This novel in vivo tool will enable us to explore the transition from an indolent to an aggressive disease and will thus permit the study of prevention and treatment options for NK-cell malignancies., (© 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. AP-1 transcription factors in cytotoxic lymphocyte development and antitumor immunity.
- Author
-
Schnoegl D, Hiesinger A, Huntington ND, and Gotthardt D
- Subjects
- Humans, Transcription Factor AP-1 metabolism, CD8-Positive T-Lymphocytes, Cytokines metabolism, T-Lymphocytes, Cytotoxic, Antineoplastic Agents, Neoplasms
- Abstract
The proper functioning of cytotoxic lymphocytes, such as natural killer and CD8+ T cells, is essential for effective cancer-immunity and immunotherapy responses. The differentiation of these cells is controlled by several transcription factors (TFs), including members of the activator protein (AP)-1 family. The activity of AP-1 family members is regulated by various immune signaling pathways, which can be triggered by activating or inhibitory receptors as well as cytokines. The target genes controlled by AP-1 TFs are central to generate immunity to pathogens or malignancies. Here, we provide an overview of the current understanding of how AP-1 TFs regulate cytotoxic lymphocytes., Competing Interests: Declaration of Competing Interest We confirm that the work is original research, has not been previously published, and has not been submitted for publication elsewhere. The authors declare no competing financial interests., (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
5. Targeting iron import to treat ANKL.
- Author
-
Gotthardt D
- Subjects
- Humans, Cell Proliferation, Transferrins, Leukemia, Large Granular Lymphocytic, Leukemia, Prolymphocytic, T-Cell
- Published
- 2023
- Full Text
- View/download PDF
6. Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis.
- Author
-
Rupp C, Bode KA, Leopold Y, Sauer P, and Gotthardt DN
- Subjects
- Adult, Aged, Aged, 80 and over, Bile immunology, Bile Duct Neoplasms immunology, Bile Duct Neoplasms pathology, Bile Ducts pathology, Case-Control Studies, Cholangiocarcinoma immunology, Cholangiocarcinoma pathology, Cholangitis, Sclerosing immunology, Cholangitis, Sclerosing pathology, Choledocholithiasis metabolism, Choledocholithiasis pathology, Cohort Studies, Cytokines analysis, Cytokines immunology, Cytokines metabolism, Female, Humans, Immunity, Innate, Lipopolysaccharide Receptors, Male, Middle Aged, Proteomics, Up-Regulation, Wnt Signaling Pathway immunology, Bile chemistry, Bile Duct Neoplasms metabolism, Bile Ducts metabolism, Cholangiocarcinoma metabolism, Cholangitis, Sclerosing metabolism
- Abstract
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown origin. Previous bile proteomic analyses in patients with PSC have revealed changes in disease activity specific to malignant transformation. In this study, we established a reference bile duct-derived bile proteome for PSC that can be used to evaluate biliary pathophysiology. Samples were collected from patients with PSC or with choledocholithiasis (control) (n=6 each). Furthermore, patients with PSC-associated cholangiocarcinoma (CC) and with CC without concomitant PSC were analyzed. None of the patients showed signs of inflammation or infection based on clinical and laboratory examinations. Proteins overexpressed in patients with PSC relative to control patients were detected by two-dimensional difference gel electrophoresis and identified by liquid chromatography-tandem mass spectrometry. Functional proteomic analysis was performed using STRING software. A total of 101 proteins were overexpressed in the bile fluid of patients with PSC but not in those of controls; the majority of these were predicted to be intracellular and related to the ribosomal and proteasomal pathways. On the other hand, 91 proteins were found only in the bile fluid of controls; most were derived from the extracellular space and were linked to cell adhesion, the complement system, and the coagulation cascade. In addition, proteins associated with inflammation and the innate immune response-e.g., cluster of differentiation 14, annexin-2, and components of the complement system-were upregulated in PSC. The most prominent pathways in PSC/CC-patients were inflammation associated cytokine and chemokine pathways, whereas in CC-patients the Wnt signaling pathway was upregulated. In PSC/CC-patients DIGE-analysis revealed biliary CD14 and Annexin-4 expression, among others, as the most prominent protein that discriminates between both cohorts. Thus, the bile-duct bile proteome of patients with PSC shows disease-specific changes associated with inflammation and the innate immune response even in the absence of obvious clinical signs of cholangitis, malignancy, or inflammation. This article is part of a Special Issue entitled: Cholangiocytes in Health and Diseaseedited by Jesus Banales, Marco Marzioni and Peter Jansen., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
7. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance.
- Author
-
Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, Strobl B, Müller M, and Sexl V
- Subjects
- Animals, Antigens, Ly metabolism, Cell Differentiation drug effects, Cell Proliferation drug effects, Cytokines pharmacology, Disease Models, Animal, Granzymes metabolism, Integrases metabolism, Interferon-gamma biosynthesis, Interferon-gamma genetics, Intestines pathology, Killer Cells, Natural cytology, Killer Cells, Natural drug effects, Kinetics, Melanoma, Experimental pathology, Mice, Mice, Inbred C57BL, Mice, Transgenic, Natural Cytotoxicity Triggering Receptor 1 metabolism, Perforin metabolism, Promoter Regions, Genetic genetics, Protein Binding drug effects, Spleen pathology, Immunologic Surveillance drug effects, Killer Cells, Natural metabolism, Neoplasms immunology, Neoplasms metabolism, STAT3 Transcription Factor metabolism
- Abstract
The members of the signal transducer and activator of transcription (STAT) family of transcription factors modulate the development and function of natural killer (NK) cells. NK cell-mediated tumor surveillance is particularly important in the body's defense against hematological malignancies such as leukemia. STAT3 inhibitors are currently being developed, although their potential effects on NK cells are not clear. We have investigated the function of STAT3 in NK cells with Stat3(Δ/Δ)Ncr1-iCreTg mice, whose NK cells lack STAT3. In the absence of STAT3, NK cells develop normally and in normal numbers, but display alterations in the kinetics of interferon-γ (IFN-γ) production. We report that STAT3 directly binds the IFN-γ promoter. In various in vivo models of hematological diseases, loss of STAT3 in NK cells enhances tumor surveillance. The reduced tumor burden is paralleled by increased expression of the activating receptor DNAM-1 and the lytic enzymes perforin and granzyme B. Our findings imply that STAT3 inhibitors will stimulate the cytolytic activity of NK cells against leukemia, thereby providing an additional therapeutic benefit., (© 2014 by The American Society of Hematology.)
- Published
- 2014
- Full Text
- View/download PDF
8. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation.
- Author
-
Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A, Schemmer P, Fischer L, Klein CG, Nadalin S, Lehner F, Settmacher U, Neuhaus P, Gotthardt D, Loss M, Ladenburger S, Paulus EM, Mertens M, and Schlitt HJ
- Subjects
- Adolescent, Adult, Aged, Cyclosporine adverse effects, Everolimus, Feasibility Studies, Female, Follow-Up Studies, Graft Rejection etiology, Graft Survival drug effects, Humans, Immunosuppressive Agents adverse effects, Male, Middle Aged, Prognosis, Prospective Studies, Sirolimus administration & dosage, Time Factors, Withholding Treatment, Young Adult, Calcineurin Inhibitors, Cyclosporine administration & dosage, Graft Rejection drug therapy, Immunosuppressive Agents administration & dosage, Liver Diseases surgery, Liver Transplantation, Sirolimus analogs & derivatives
- Abstract
The feasibility of de novo everolimus without calcineurin inhibitor (CNI) therapy following liver transplantation was assessed in a multicenter, prospective, open-label trial. Liver transplant patients were randomized at 4 weeks to start everolimus and discontinue CNI, or continue their current CNI-based regimen. The primary endpoint was adjusted estimated GFR (eGFR; Cockcroft-Gault) at month 11 post randomization. A 24-month extension phase followed 81/114 (71.1%) of eligible patients to month 35 post randomization. The adjusted mean eGFR benefit from randomization to month 35 was 10.1 mL/min (95% confidence interval [CI] -1.3, 21.5 mL/min, p = 0.082) in favor of CNI-free versus CNI using Cockcroft-Gault, 9.4 mL/min/1.73 m(2) (95% CI -0.4, 18.9, p = 0.053) with Modification of Diet in Renal Disease (four-variable) and 9.5 mL/min/1.73 m(2) (95% CI -1.1, 17.9, p = 0.028) using Nankivell. The difference in favor of the CNI-free regimen increased gradually over time due to a small progressive decline in eGFR in the CNI cohort despite a reduction in CNI exposure. Biopsy-proven acute rejection, graft loss and death were similar between groups. Adverse events led to study drug discontinuation in five CNI-free patients and five CNI patients (12.2% vs. 12.5%, p = 1.000) during the extension phase. Everolimus-based CNI-free immunosuppression is feasible following liver transplantation and patients benefit from sustained preservation of renal function versus patients on CNI for at least 3 years., (© 2014 The Authors. American Journal of Transplantation Published by Wiley Periodicals, Inc. on behalf of American Society of Transplant Surgeons.)
- Published
- 2014
- Full Text
- View/download PDF
9. Anserine inhibits carnosine degradation but in human serum carnosinase (CN1) is not correlated with histidine dipeptide concentration.
- Author
-
Peters V, Jansen EE, Jakobs C, Riedl E, Janssen B, Yard BA, Wedel J, Hoffmann GF, Zschocke J, Gotthardt D, Fischer C, and Köppel H
- Subjects
- Adult, Anserine blood, Carnosine blood, Female, Histidine blood, Humans, Liver Cirrhosis blood, Liver Cirrhosis enzymology, Liver Cirrhosis metabolism, Male, Middle Aged, Young Adult, Anserine metabolism, Carnosine metabolism, Dipeptidases metabolism, Histidine metabolism
- Abstract
Background: We reported an association of a particular allele of the carnosinase (CNDP1 Mannheim) gene with reduced serum carnosinase (CN1) activity and absence of nephropathy in diabetic patients. Carnosine protects against the adverse effects of high glucose levels but serum carnosine concentration was generally low., Methods: We measured the concentration of two further histidine dipeptides, anserine and homocarnosine, via HPLC. CN1 activity was measured fluorometically and for concentration we developed a capture ELISA., Results: We found an association between the CNDP1 Mannheim allele and reduced serum CN1 activity for all three dipeptides but no correlation to serum concentrations although anserine and homocarnosine inhibited carnosinase activity. Patients with liver cirrhosis have low CN1 activity (0.24 ± 0.17 μmol/ml/h, n=7 males; normal range: 3.2 ± 1.1, n=104; p<0.05) and CN1 concentrations (2.3 ± 1.5 μg/ml; normal range: 24.9 ± 8.9, p<0.05) but surprisingly, histidine dipeptide concentrations in serum are not increased compared to controls., Conclusions: Serum histidine dipeptide concentrations are not correlated to CN1 activity. The protective effect of low CN1 activity might be related either to turnover of CN1 substrates or a protective function of dipeptides might be localized in other tissues., (Copyright © 2010 Elsevier B.V. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
10. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival.
- Author
-
Rudolph G, Gotthardt D, Kloeters-Plachky P, Rost D, Kulaksiz H, and Stiehl A
- Subjects
- Adolescent, Adult, Aged, Cholangitis, Sclerosing therapy, Cholestasis epidemiology, Comorbidity, Female, Follow-Up Studies, Humans, Incidence, Inflammatory Bowel Diseases epidemiology, Kaplan-Meier Estimate, Liver Transplantation, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Survival Rate, Ursodeoxycholic Acid therapeutic use, Young Adult, Bile Duct Neoplasms epidemiology, Cholangitis, Sclerosing complications, Cholangitis, Sclerosing mortality, Cholestasis complications, Colorectal Neoplasms epidemiology, Gallbladder Neoplasms epidemiology, Inflammatory Bowel Diseases complications
- Abstract
Background & Aims: In patients with primary sclerosing cholangitis (PSC) treated with ursodeoxycholic acid (UDCA), dominant stenoses are associated with reduced survival free of liver transplantation and the role of inflammatory bowel disease (IBD) in such patients is unclear. In the present study the influence of IBD on the outcome in patients with and without dominant stenosis has been evaluated., Methods: In a prospective study, 171 patients were followed for up to 20 years. All patients were treated with ursodeoxycholic acid; patients with dominant stenosis in addition were treated endoscopically., Results: A total of 97 out of 171 patients had or developed dominant bile duct stenoses and 96 out of 97 were treated endoscopically. In patients with dominant stenosis without IBD, no carcinoma was found whereas all six bile duct and two gallbladder carcinomas and 6/7 colo-rectal carcinomas were found in patients with dominant stenosis with IBD (p=0.012). In patients without dominant stenosis but with IBD, 1 out of 7 had colo-rectal carcinoma. In patients with dominant stenosis without IBD (n=30), actuarial survival free of liver transplantation at 18 years was 77.8% and in those with dominant stenosis and inflammatory bowel disease (n=67) it was 23.0% (p=0.045). In PSC patients without dominant stenosis and without IBD (n=21), actuarial survival free of liver transplantation at 18 years was 68.2% and in those with inflammatory bowel disease (n=53) it was 78.4% (n.s.)., Conclusions: In patients without dominant stenosis, IBD had no effect on the incidence of carcinomas and survival. Only patients with dominant stenosis with additional IBD had an increased carcinoma rate. This may contribute to the reduced survival free of liver transplantation in such patients., (Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
11. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis.
- Author
-
Rudolph G, Gotthardt D, Klöters-Plachky P, Kulaksiz H, Rost D, and Stiehl A
- Subjects
- Adolescent, Adult, Aged, Anti-Bacterial Agents therapeutic use, Child, Cholangitis, Sclerosing complications, Cholangitis, Sclerosing drug therapy, Cholestasis therapy, Female, Humans, Liver Transplantation, Male, Middle Aged, Prospective Studies, Ursodeoxycholic Acid therapeutic use, Bacteria isolation & purification, Bile microbiology, Candida isolation & purification, Cholangitis, Sclerosing mortality, Cholestasis complications
- Abstract
Background/aims: In primary sclerosing cholangitis (PSC) dominant stenoses are frequently associated with bacterial, and in part, also fungal infections of the bile ducts. In the present study, the influence of dominant stenoses and of biliary infections on the long-term outcome was studied., Methods: In a prospective study, 171 patients were followed up for 20 years. All patients were treated with ursodeoxycholic acid. Dominant stenoses were treated endoscopically and during endoscopic procedures, bile was obtained for microbiologic analysis., Results: Of the 171 patients, 97 had or developed major bile duct stenoses and 96/97 were treated endoscopically. In the 55/97 patients with dominant stenosis, bile samples were obtained and of these, 41/55 had bacteria, five had also Candida and 2/55 had only Candida in their bile. Survival free of liver transplantation in patients without dominant stenosis at 18 years was 73.1% and of patients with dominant stenosis was 25.0% (p=0.011). Bacteria in bile had no effect on survival whereas Candida in bile was associated with reduced survival (p=0.025)., Conclusions: In patients with dominant stenosis, survival free of liver transplantation is reduced. Bacteria in bile do not worsen the outcome if dominant stenoses are opened endoscopically and infection is adequately treated with antibiotics. Candida in bile is associated with a poor prognosis and these patients need liver transplantation relatively soon.
- Published
- 2009
- Full Text
- View/download PDF
12. Copper-induced translocation of the Wilson disease protein ATP7B independent of Murr1/COMMD1 and Rab7.
- Author
-
Weiss KH, Lozoya JC, Tuma S, Gotthardt D, Reichert J, Ehehalt R, Stremmel W, and Füllekrug J
- Subjects
- Adaptor Proteins, Signal Transducing, Adenosine Triphosphatases genetics, Biological Transport physiology, Biomarkers metabolism, Carrier Proteins genetics, Cation Transport Proteins genetics, Cell Line, Copper-Transporting ATPases, Endosomes metabolism, Humans, RNA Interference, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins metabolism, rab GTP-Binding Proteins genetics, rab7 GTP-Binding Proteins, Adenosine Triphosphatases metabolism, Carrier Proteins metabolism, Cation Transport Proteins metabolism, Copper metabolism, rab GTP-Binding Proteins metabolism
- Abstract
Wilson disease is a genetic disorder of copper metabolism. Impaired biliary excretion results in a gradual accumulation of copper, which leads to severe disease. The specific gene defect lies in the Wilson disease protein, ATP7B, a copper-transporting ATPase that is highly active in hepatocytes. The two major functions of ATP7B in the liver are the copper loading of ceruloplasmin in the Golgi apparatus, and the excretion of excess copper into the bile. In response to elevated copper levels, ATP7B shows a unique intracellular trafficking pattern that is required for copper excretion from the Golgi apparatus into dispersed vesicles. We analyzed the translocation of ATP7B by both confocal microscopy and RNA interference, testing current models that suggest the involvement of Murr1/COMMD1 and Rab7 in this pathway. We found that although the ATP7B translocation is conserved among nonhepatic cell lines, there is no co-localization with Murr1/COMMD1 or the Rab marker proteins of the endolysosomal system. Consistent with this finding, the translocation of ATP7B was not impaired by the depletion of either Murr1/COMMD1 or Rab7, or by a dominant-negative Rab7 mutant. In conclusion, our data suggest that the translocation of ATP7B takes place independently of Rab7-regulated endosomal traffic events. Murr1/COMMD1 plays a role in a later step of the copper excretion pathway but is not involved in the translocation of the Wilson disease protein.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.